BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld Science, Respiratory

BioWorld Science, Respiratory
BioWorld Science, Respiratory RSS Feed RSS

Inflammatory

Deepcure discovers oral STAT6 inhibitors for type 2 inflammatory diseases

Dec. 20, 2024
Deepcure Inc. has discovered potent, selective oral small-molecule inhibitors of STAT6. These next-generation STAT6 inhibitors have demonstrated promising oral bioavailability, cell permeability and metabolic stability, and do not target STAT6 for degradation.
Read More
Immune

TAVO-101, a potent anti-TSLP antibody with extended half-life

Dec. 19, 2024
Researchers from Tavotek Biotherapeutics Inc. described the discovery and preclinical characterization of TAVO-101.
Read More
Respiratory

Haisco Pharmaceutical discovers new integrin αvβ1 and αvβ6 antagonists for IPF

Dec. 10, 2024
Haisco Pharmaceutical Group Co. Ltd. has described compounds acting as integrin αvβ1 and/or αvβ6 antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Read More
Illustration of receptor binding site of the A/Texas/37/2024 hemagglutinin Leu226 mutant
Infection

A single mutation in H5N1 is all that’s needed for easier transmissibility

Dec. 9, 2024
By Mar de Miguel
Although it does not generally infect humans, a single mutation of the H5N1 virus in the highly pathogenic avian and bovine clade 2.3.4.4b could overcome this barrier and possibly trigger a pandemic. Scientists at The Scripps Research Institute have warned of this possibility after studying the three-dimensional structure of the viral hemagglutinin and seeing how a change in one amino acid would make it more suitable for the human cell receptor. The researchers stress the need to monitor new mutations of this virus in order to act quickly in case the global jump to our species occurs.
Read More
Art concept for inflamed human tissue
Respiratory

Refoxy Pharmaceuticals raises funding to advance FOXO3 therapeutics for IPF

Dec. 5, 2024
Refoxy Pharmaceuticals GmbH has announced a €9.1 million (US$9.6 million) seed-extension financing to support its research.
Read More
Lungs anatomy
Respiratory

Selective TNIK inhibitor ameliorates idiopathic pulmonary fibrosis

Dec. 3, 2024
TRAF2- and NCK-interacting kinase (TNIK) has been reported as a therapeutic target for colorectal cancer and, more recently, for lung squamous cell carcinoma, triple-negative breast cancer, or ovarian cancer, among others, especially in combination with inhibiting cancer-related kinases.
Read More
Respiratory

FDA awards orphan drug designation to Alveogene’s gene therapy for SP-B deficiency

Dec. 3, 2024
Alveogene Ltd. has announced its novel inhaled gene therapy for lethal neonatal surfactant protein B (SP-B) deficiency, AVG-002, has been awarded orphan drug designation by the FDA.
Read More
Art concept for inflamed human tissue
Respiratory

GSK-3179106 reduces inflammation and acute lung injury in mice through p38 MAPK targeting

Nov. 29, 2024
Previous laboratory and clinical studies showed that inhibiting the activation of the MAPK signaling pathway could attenuate acute lung injury.
Read More
Respiratory

New MRGPRX2 antagonists disclosed in Septurna patent

Nov. 26, 2024
Septerna Inc. has divulged compounds acting as mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of asthma, cancer, multiple sclerosis, obesity, osteoarthritis, psoriasis, rheumatoid arthritis and ulcerative colitis, among others.
Read More
D-rendered image showing atlas of human embryonic skeletal development
Drug design, drug delivery & technologies

More than 100M cells included in the human cell atlas

Nov. 21, 2024
By Mar de Miguel
An international consortium of thousands of scientists is creating the Human Cell Atlas, a three-dimensional map of all the cells in the body. The goal is to understand all the cells that make up human tissues, organs and systems, which will enable multiple medical applications. This collection of cell maps is openly available for navigation at single-cell resolution, identified through omics analyses that reveal the tridimensional distribution of each cell.
Read More
Previous 1 2 … 12 13 14 15 16 17 18 19 20 … 693 694 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • Antibodies attacking cancer cell

    ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal

    BioWorld
    Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing